Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

1608435

registered interest
date	28/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, following the decision by the Joint Committee on Vaccination and Immunisation that family members of, and carers for, people in the clinical risk groups are not recommended to receive COVID-19 booster vaccinations, what steps they are taking to protect people in clinical risk groups from contracting COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL6941
answer	answer is ministerial correction date of answer 12/04/2023 answer text <p>As set out in the Written Ministerial Statement titled ‘Approach to Managing Covid-19’ on 30 March 2023, in 2023/24 the Government will maintain a range of capabilities to protect those at higher risk of severe illness from COVID-19. Given the continued effectiveness of vaccines and improved treatments, for most people there is a much lower risk of severe illness compared to earlier in the pandemic.</p><p> </p><p>We will therefore continue to encourage people to take up the vaccines to which they are entitled, and we will continue to fund and provide COVID-19 testing, to manage outbreaks in some high-risk settings and to enable access to treatments for those who are eligible. We will also maintain essential COVID-19 surveillance activities in the community, primary and secondary care, and in high-risk settings. Additionally, we will retain proportionate capability for testing in the event of a COVID-19 wave or variant that results in a significant increase in pressure on the National Health Service.</p><p> </p><p>Vaccination does not significantly limit transmission, so there is no strong reason to prioritise vaccination for carers of those who are at high risk of severe illness.</p> answering member printed Lord Markham question first answered 12/04/2023 13:39:05 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1601499

registered interest
date	06/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 14 February (HL5363), what data they are utilising (1) to monitor emerging COVID-19 variants, and (2) to assess their potential impact; and what specific surveillance arrangements are in place to assist this assessment.
tabling member printed	Lord Mendelsohn
uin	HL6154
answer	answer is ministerial correction date of answer 16/03/2023 answer text <p>The UK Health Security Agency (UKHSA) undertakes regular monitoring of United Kingdom and international SARS-CoV-2 genomic data to detect and characterise new variants. In the UK, this includes data from routine testing and surveillance studies, with variant evaluation currently based on data from multiple sources. UK genomics surveillance is primarily conducted through healthcare associated sites such as hospitals and Office for National Statistics community sampling, with international data being obtained from the Global Initiative on Sharing Avian Influenza Data which includes genetic sequence and related clinical and epidemiological data.</p><p> </p><p>The potential impact is considered first based on the relative fitness advantage (the lineage growth rate), national and international geographic dispersion, and/or mutation profile in relation to immune response or therapeutic efficacy, using genomic sequence data. Analysis is discussed at multidisciplinary expert meetings where further laboratory virology investigations can be triggered to add confidence to the risk assessment.</p><p> </p><p>UKHSA is utilising strong surveillance capabilities, rooted in the highest-quality data systems, data architecture and analytics to anticipate, prepare for and respond to health risks, including emerging COVID-19 variants. UKHSA is currently working with the Department to consider next steps for the future of surveillance programmes.</p> answering member printed Lord Markham question first answered 16/03/2023 16:56:03 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1537036

registered interest
date	27/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Government Counter-Fraud Function’s previous estimate that 57 per cent of COVID-19 expenditure was at ”a high or very high fraud risk”, what is their current estimate of the level of risk surrounding COVID-19 health expenditure.
tabling member printed	Lord Sikka
uin	HL2990
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>We estimate that approximately 49% to 51% of COVID-19 health expenditure is at high or very high level of fraud risk.</p> answering member printed Lord Markham question first answered 08/11/2022 13:09:29 answering member 4948 label Biography information for Lord Markham
tabling member	4885 label Biography information for Lord Sikka

1491743

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they have plans to publicise findings from the SIREN study, and data from this and other studies about the protective effects against reinfection and serious illness of infection-acquired immunity (unboosted by vaccination).
tabling member printed	Lord Farmer
uin	HL2009
answer	answer is ministerial correction date of answer 02/08/2022 answer text <p>Scientific papers and reports from the SIREN study are being publicised online through the UK Health Security Agency (UKHSA) and in scientific journals. In addition, the study’s participant retention programme includes regular webinars, newsletters and videos to share its results and findings.</p><p> </p><p>On 22 July 2022, the UKHSA published SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 44 with data on trends in primary infections and reinfections. A copy of the technical briefing is attached.</p><p>The Office for National Statistics’ COVID-19 Infection Survey publishes analysis on re-infections and the associated risk factors and symptoms. An updated assessment, Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19, UK: 20 July 2022. Characteristics of people testing positive for COVID-19 from the Coronavirus (COVID-19) Infection Survey, was published on 20 July 2022. A copy of the assessment is attached.</p> answering member printed Lord Kamall attachment 1 file name SARS-CoV-2 variants of concern and variants under investigation_ technical briefing 44 (22 July 2022) (1).pdf title Sars 2 file name Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19, UK - Office for National Statistics (1).pdf title Survey question first answered 02/08/2022 12:20:41 answering member 4909 label Biography information for Lord Kamall
tabling member	4321 label Biography information for Lord Farmer

1464287

registered interest
date	18/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 27 April (HL7561), what conclusions they have reached following meetings with groups representing the immunocompromised community on how they can be involved in (1) creating, and (2) disseminating, (a) communication, and (b) guidance, to people about how to safely manage their ongoing risk.
tabling member printed	Lord Mendelsohn
uin	HL347
answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL348 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1464288

registered interest
date	18/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to (1) communicate, and (2) consult, with (a) charities, and (b) patient organisations, as part of the COVID-19 enhanced protection programme (EPP); and what format this will take.
tabling member printed	Lord Mendelsohn
uin	HL348
answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1464289

registered interest
date	18/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government who is responsible for leading the COVID-19 enhanced protection programme (EPP); and what is the process for (1) charities, and (2) patient organisations, to be designated as stakeholders for the programme.
tabling member printed	Lord Mendelsohn
uin	HL349
answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL348 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn